Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QWINT-3: LY3209590 vs insulin degludec in type 2 diabetes on basal insulin
2021-002569-16Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Started Feb 2022; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-002569-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002569-16.